✳ GrantAtlasSign in ↗
← All opportunities

forecasted

Applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics

Food and Drug Administration · FOR-FD-25-015

Award range

See source for award amount

Deadline

Not specified

Eligible applicants

For profit organizations other than small businesses, Special district governments, Independent school districts, Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility", Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Native American tribal governments (Federally recognized), State governments, County governments, City or township governments, Small businesses, Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Public and State controlled institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education

Geographic eligibility and all attachment-specific conditions require review of the original announcement.

Matching funds & resources

Source matching-funds field: Not Required.

Matching funds and leveraged resources are different requirements. Read the description and reviewed rules below before determining resource commitments.

About this opportunity

The goal of this funding opportunity announcement is to support applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics. The main outcomes of this work will be publications and presentations; however, FDA staff anticipate substantial involvement in study design and reviewing interim deliverables to ensure that the studies develop practical approaches and solutions that have the potential to inform regulatory decision making in the future. We anticipate organizing regular calls with funded investigators to support the collaboration with FDA - reviewing annual reports would be insufficient to ensure that direction of the research addresses FDA's needs. OCE is interested in supporting research that improve the detection, monitoring and treatment of cardiotoxicity of oncology therapeutics. Specific areas of interest include: -Standardize Definitions: Develop clear definitions for different types and grades of cardiotoxicity -Biomarkers and Imaging: Standardize the use of biomarkers and imaging techniques for assessing cardiotoxicity in oncology trials -Functional Measures: Define consistent criteria for evaluating cardiac function -Monitoring Plan: Develop a standardized cardiotoxicity monitoring plan that specifies the timing of cardiac assessments during the trial. -Risk Stratification: Use a risk stratification model to identify patients at higher risk for cardiotoxicity based on pre-existing conditions and treatment regimens. -Electronic Health Records and Real-World Data: Utilize electronic health records to standardize and systematically collect and store cardiotoxicity data, ensuring data accuracy and completeness. -Patient-Reported Outcomes: Integrate patient-reported outcomes related to cardiovascular health (e.g., symptoms of heart failure, quality of life). -Collaborative Networks: Engage in collaborative networks with other research institutions and industry partners to share data, best practices, and insights. -Public Databases: Contribute to and utilize public databases of cardiotoxicity data to enhance the generalizability of findings and support broader research efforts. -Treatment: Develop innovative approaches to treat cardiotoxicities with new oncology therapeutics. -Natural history: Studies to investigate the natural history of various cardiotoxicities with new oncology therapeutics.

Funding geography: Not specified — review source. A funder’s address does not establish eligibility.

Review original source ↗

Funding instrument: Cooperative Agreement. Issuing jurisdiction: Federal. This is not a geographic eligibility determination.

Source fields and evidence

id: 357261
Source ↗ · id

opportunityNumber: FOR-FD-25-015
Source ↗ · opportunityNumber

opportunityTitle: Applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics
Source ↗ · opportunityTitle

revision: 0
Source ↗ · revision

agencyDetails: {"code":"FDA","seed":"HHS-FDA","agencyName":"Food and Drug Administration","agencyCode":"HHS-FDA","topAgencyCode":"HHS"}
Source ↗ · agencyDetails

owningAgencyCode: HHS-FDA
Source ↗ · owningAgencyCode

cfdas: [{"id":425390,"opportunityId":357261,"cfdaNumber":"93.103","programTitle":"Food and Drug Administration Research"}]
Source ↗ · cfdas

forecastDesc: <p>The goal of this funding opportunity announcement is to support applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics. The main outcomes of this work will be publications and presentations; however, FDA staff anticipate substantial involvement in study design and reviewing interim deliverables to ensure that the studies develop practical approaches and solutions that have the potential to inform regulatory decision making in the future. We anticipate organizing regular calls with funded investigators to support the collaboration with FDA - reviewing annual reports would be insufficient to ensure that direction of the research addresses FDA's needs.</p><p><br></p><p>OCE is interested in supporting research that improve the detection, monitoring and treatment of cardiotoxicity of oncology therapeutics.</p><p>Specific areas of interest include:</p><p>-Standardize Definitions: Develop clear definitions for different types and grades of cardiotoxicity</p><p>-Biomarkers and Imaging: Standardize the use of biomarkers and imaging techniques for assessing cardiotoxicity in oncology trials</p><p>-Functional Measures: Define consistent criteria for evaluating cardiac function</p><p>-Monitoring Plan: Develop a standardized cardiotoxicity monitoring plan that specifies the timing of cardiac assessments during the trial.</p><p>-Risk Stratification: Use a risk stratification model to identify patients at higher risk for cardiotoxicity based on pre-existing conditions and treatment regimens.</p><p>-Electronic Health Records and Real-World Data: Utilize electronic health records to standardize and systematically collect and store cardiotoxicity data, ensuring data accuracy and completeness.</p><p>-Patient-Reported Outcomes: Integrate patient-reported outcomes related to cardiovascular health (e.g., symptoms of heart failure, quality of life).</p><p>-Collaborative Networks: Engage in collaborative networks with other research institutions and industry partners to share data, best practices, and insights.</p><p>-Public Databases: Contribute to and utilize public databases of cardiotoxicity data to enhance the generalizability of findings and support broader research efforts.</p><p>-Treatment: Develop innovative approaches to treat cardiotoxicities with new oncology therapeutics.</p><p>-Natural history: Studies to investigate the natural history of various cardiotoxicities with new oncology therapeutics.</p><p><br></p>
Source ↗ · forecastDesc

applicantTypes: [{"id":"22","description":"For profit organizations other than small businesses"},{"id":"04","description":"Special district governments"},{"id":"05","description":"Independent school districts"},{"id":"99","description":"Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled \"Additional Information on Eligibility\""},{"id":"12","description":"Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"07","description":"Native American tribal governments (Federally recognized)"},{"id":"00","description":"State governments"},{"id":"01","description":"County governments"},{"id":"02","description":"City or township governments"},{"id":"23","description":"Small businesses"},{"id":"08","description":"Public housing authorities/Indian housing authorities"},{"id":"11","description":"Native American tribal organizations (other than Federally recognized tribal governments)"},{"id":"06","description":"Public and State controlled institutions of higher education"},{"id":"13","description":"Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"20","description":"Private institutions of higher education"}]
Source ↗ · applicantTypes

fundingInstruments: [{"id":"CA","description":"Cooperative Agreement"}]
Source ↗ · fundingInstruments

fundingActivityCategories: [{"id":"AG","description":"Agriculture"},{"id":"CP","description":"Consumer Protection"},{"id":"FN","description":"Food and Nutrition"}]
Source ↗ · fundingActivityCategories

costSharing: false
Source ↗ · costSharing

lastUpdatedDate: Nov 20, 2024 02:40:16 PM EST
Source ↗ · lastUpdatedDate

status: forecasted
Source ↗ · oppHits[id=357261].oppStatus

Source retrieved 10/15/2026 · Revision 0. Always confirm current requirements and dates with the funder. Structured source fields are checked; this is not a determination that every applicant qualifies.

Build your funding pipeline.

Save opportunities, filter by fit, and export your deadlines with membership.

View plans from $49/month ↗